DarioHealth Shareholders Back Governance, Capital and Equity Plans

An update from DarioHealth ( (DRIO) ) is now available.

On January 29, 2026, DarioHealth Corp. held its 2026 Annual Meeting of Stockholders, where shareholders elected all nominated directors to serve until the next annual meeting and ratified Kesselman & Kesselman, a member of PricewaterhouseCoopers International, as the company’s independent auditor for the 2026 fiscal year. Investors approved the ratification of conversions and issuances related to the company’s Series D, D-1, D-2, and D-3 preferred stock from private placements completed in December 2024 and January 2025, as well as additional common shares tied to Series B and C preferred stock arrangements, reinforcing prior capital-raising and balance sheet initiatives. Shareholders also ratified the issuance of common shares linked to warrants and restricted stock units issued in connection with DarioHealth’s acquisition of Twill Inc., supporting the integration of that strategic transaction, and authorized an increase of 500,000 shares under the 2020 Equity Incentive Plan, enhancing the company’s capacity to use equity compensation to attract and retain talent. In addition, stockholders backed a non-binding advisory resolution approving executive compensation practices and passed an amendment to the company’s Certificate of Incorporation granting the board the authority to amend the bylaws, collectively signaling strong shareholder support for the current governance structure, capital strategy, and leadership.

The most recent analyst rating on (DRIO) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.

Spark’s Take on DRIO Stock

According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.

The score is held back primarily by weak financial performance—large losses and ongoing cash burn—despite improving gross margins and manageable leverage. The earnings call adds support via optimistic 2026 guidance, cost-reduction plans, and strong retention/pipeline, while technicals are mixed-to-neutral and valuation remains difficult to justify with a negative P/E and no dividend.

To see Spark’s full report on DRIO stock, click here.

More about DarioHealth

DarioHealth Corp. operates in the digital health sector, providing technology-enabled solutions for chronic condition management and patient engagement. The company focuses on integrating data-driven tools and connected devices to support healthcare outcomes and value-based care for payers, providers, and patients.

Average Trading Volume: 24,002

Technical Sentiment Signal: Strong Sell

Current Market Cap: $74.82M

Find detailed analytics on DRIO stock on TipRanks’ Stock Analysis page.